BioNexus Gene Lab Corp

NAS:BGLC (Malaysia)   Ordinary Shares
$ 0.52 -0.024 (-4.41%) 10:08 PM EST
At Loss
P/B:
0.98
Volume:
24.86K
Avg Vol (2M):
167.47K
Volume:
24.86K
At Loss
Avg Vol (2M):
167.47K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for BioNexus Gene Lab Corp ( ) from 2020 to May 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. BioNexus Gene Lab stock (BGLC) PE ratio as of May 28 2024 is 0. More Details

BioNexus Gene Lab Corp (BGLC) PE Ratio (TTM) Chart

To

BioNexus Gene Lab Corp (BGLC) PE Ratio (TTM) Historical Data

Total 930
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 11
BioNexus Gene Lab PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-04-01 At Loss 2024-01-25 At Loss
2024-03-28 At Loss 2024-01-24 At Loss
2024-03-27 At Loss 2024-01-23 At Loss
2024-03-26 At Loss 2024-01-22 At Loss
2024-03-25 At Loss 2024-01-19 At Loss

BioNexus Gene Lab Corp (BGLC) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.